What to watch on Akero’s MASH-cirrhosis study results next month

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I’m suffering from post-JPM Week malaise. Not sick, thankfully, just the mental hangover that follows all that San Francisco nuttiness.

What to watch for when Akero reports MASH-cirrhosis study results next month

a liver made up by geometric shapes – biotech coverage from STAT — Illustration of human liver with faceted low-poly geometry effectAdobe

In February, Akero Therapeutics will be reporting results from a nearly two-year, placebo-controlled study of its drug efruxifermin in patients with cirrhosis caused by the fatty liver disease known as MASH.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Briya Raises $11.5M for Healthcare Blockchain-Secured Data Exchange Platform

What You Should Know: Briya, an end-to-end healthcare data exchange platform, today announced completion of an $11.5 million Series A round of financing, bringing the company’s

September 19, 2023

Opinion | ‘It’s Not a First-World Problem’: What We Heard This Week

“It’s not a first-world problem and it’s not a Western-world problem.” — Punith Kempegowda, MBBS, MD, PhD, MSc, of the University of Birmingham in England,

June 26, 2023

Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high

August 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.